Literature DB >> 15310457

Mitochondria as cancer drug targets.

Anthony S Don1, Philip J Hogg.   

Abstract

Cancer cells are defined by their unlimited replicative potential and resistance to cell death stimuli. It is generally considered that a point of no return in apoptotic cell death is the permeabilisation of the mitochondrial membranes. For this reason, agents that permeabilise cancer cell mitochondria have the potential to circumvent their resistance to apoptotic cell death. Fortunately, the proliferative and bioenergetic differences between normal and cancerous cells provide an opportunity to selectively target cancer cell mitochondria.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15310457     DOI: 10.1016/j.molmed.2004.06.005

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  26 in total

1.  Mitaplatin increases sensitivity of tumor cells to cisplatin by inducing mitochondrial dysfunction.

Authors:  Xue Xue; Song You; Qiang Zhang; Yan Wu; Guo-Zhang Zou; Paul C Wang; Yu-Liang Zhao; Yan Xu; Lee Jia; Xiaoning Zhang; Xing-Jie Liang
Journal:  Mol Pharm       Date:  2012-02-13       Impact factor: 4.939

2.  Immunohistochemical expression of mitochondrial membrane complexes (MMCs) I, III, IV and V in malignant and benign periampullary epithelium: a potential target for drug therapy of periampullary cancer?

Authors:  Mark M Aloysius; Abed M Zaitoun; Timothy E Bates; Mohammad Ilyas; Dumitru Constantin-Teodosiu; Brian J Rowlands; Dileep N Lobo
Journal:  BMC Cancer       Date:  2010-03-04       Impact factor: 4.430

Review 3.  Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria.

Authors:  S P Mathupala; Y H Ko; P L Pedersen
Journal:  Oncogene       Date:  2006-08-07       Impact factor: 9.867

4.  AIF suppresses chemical stress-induced apoptosis and maintains the transformed state of tumor cells.

Authors:  Alexander Urbano; Umayal Lakshmanan; Poh Heok Choo; Jair Chau Kwan; Poh Yong Ng; Ke Guo; Saravanakumar Dhakshinamoorthy; Alan Porter
Journal:  EMBO J       Date:  2005-07-07       Impact factor: 11.598

Review 5.  Inhibitors of succinate: quinone reductase/Complex II regulate production of mitochondrial reactive oxygen species and protect normal cells from ischemic damage but induce specific cancer cell death.

Authors:  Stephen J Ralph; Rafael Moreno-Sánchez; Jiri Neuzil; Sara Rodríguez-Enríquez
Journal:  Pharm Res       Date:  2011-08-24       Impact factor: 4.200

6.  Vitamin E Derivative with Modified Side Chain Induced Apoptosis by Modulating the Cellular Lipids and Membrane Dynamics in MCF7 Cells.

Authors:  Seher Gok; Oleksandr Kuzmenko; Andrii Babinskyi; Feride Severcan
Journal:  Cell Biochem Biophys       Date:  2021-01-13       Impact factor: 2.194

7.  Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate.

Authors:  Shanta Dhar; Stephen J Lippard
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-10       Impact factor: 11.205

Review 8.  Molecular oncology focus - is carcinogenesis a 'mitochondriopathy'?

Authors:  Anna M Czarnecka; Jerzy S Czarnecki; Wojciech Kukwa; Francesco Cappello; Anna Scińska; Andrzej Kukwa
Journal:  J Biomed Sci       Date:  2010-04-25       Impact factor: 8.410

9.  Suppression of lung tumorigenesis by leucine zipper/EF hand-containing transmembrane-1.

Authors:  Soon-Kyung Hwang; Longzhen Piao; Hwang-Tae Lim; Arash Minai-Tehrani; Kyeong-Nam Yu; Youn-Cheol Ha; Chan-Hee Chae; Kee-Ho Lee; George R Beck; Jongsun Park; Myung-Haing Cho
Journal:  PLoS One       Date:  2010-09-02       Impact factor: 3.240

10.  The Amaryllidaceae isocarbostyril narciclasine induces apoptosis by activation of the death receptor and/or mitochondrial pathways in cancer cells but not in normal fibroblasts.

Authors:  Patrick Dumont; Laurent Ingrassia; Sébastien Rouzeau; Fabrice Ribaucour; Stéphanie Thomas; Isabelle Roland; Francis Darro; Florence Lefranc; Robert Kiss
Journal:  Neoplasia       Date:  2007-09       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.